华泰联合证券有限责任公司 关于通化东宝药业股份有限公司 2024 年度募集资金存放与使用情况的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作为 通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"）非公开发行股票持 续督导保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所股 票上市规则》、《上海证券交易所上市公司自律监管指引第 11 号——持续督导》、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定，对 通化东宝 2024 年度募集资金的存放和使用情况进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2016]918 号文批准，公司由主承销商 华泰联合证券采用非公开发行方式，向特定投资者非公开发行人民币普通股（A 股）股票 55,726,976 股，发行价格为每股人民币 18.68 元，本次发行共计募集资 金人民币 1,040,979,911.68 元，扣除承销费用 19,948,774.13 元后的募集资金为 1,021,031 ...

通化东宝药业股份有限公司 募集资金存放与使用情况鉴证报告 （2024 年度） 目 录 页 次 一、 募集资金存放与使用情况鉴证报告 1-2 二、 通化东宝药业股份有限公司 2024 年度募集资 金存放与实际使用情况的专项报告 1-12 募集资金存放与使用情况鉴证报告 德皓核字[2025]00000928 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 通化东宝药业股份有限公司 我们审核了后附的通化东宝药业股份有限公司（以下简称通化东 宝）《2024 年度募集资金存放与实际使用情况的专项报告》（以下简 称"募集资金专项报告"）。 一、董事会的责任 通化东宝董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第 2 号―上市公司募集资金管理和使用的监管要求》、 《上海证券交易所上市公司自律监管指引第 1 号-规范运作》和《上 海证券交易所上市公司自律监管指南第 1 号-公告格式》的相关规定 编制募 ...

通化东宝药业股份有限公司 2024年度独立董事述职报告（毕焱） （二）独立董事独立性的情况说明 报告期内，本人任职符合《上市公司独立董事管理办法》等法律法规关于独 立性的要求，不存在影响独立性的情况。 二、独立董事 2024 年度履职概况 作为通化东宝药业股份有限公司(以下简称"公司"或"本公司")的独立 董事,在2024年度内，本人严格按照《公司法》、《证券法》、《上市公司独立 董事管理办法》、《上海证券交易所上市公司自律监管指引第1号——规范运作》 等有关法律、法规的规定及《公司章程》的有关规定和要求，勤勉、忠实、尽责 地履行独立董事职责,不受公司控股股东、实际控制人或者其他与公司存在利害 关系的单位与个人的影响,积极出席公司股东大会和董事会,发挥专业特长,对公 司的重大事项发表了客观、公正的意见，切实维护了公司和全体股东的合法权益。 现将2024年度工作情况报告如下: 一、独立董事基本情况 （一）工作履历、专业背景以及兼职情况 毕焱，女，汉族，出生于 1966 年 12 月，中共党员，高级会计师、注册会计 师，大学本科学历。1989 年毕业于吉林财贸学院（现吉林财经大学）会计学专 业，获经济学学士学位， ...

通化东宝药业股份有限公司 2024年度独立董事述职报告（徐岱） 作为通化东宝药业股份有限公司(以下简称"公司"或"本公司")的独立 董事,在2024年度内，本人严格按照《公司法》、《证券法》、《上市公司独立 董事管理办法》、《上海证券交易所上市公司自律监管指引第1号——规范运作》 等有关法律、法规的规定及《公司章程》的有关规定和要求，勤勉、忠实、尽责 地履行独立董事职责,不受公司控股股东、实际控制人或者其他与公司存在利害 关系的单位与个人的影响,积极出席公司股东大会和董事会,发挥专业特长,对公 司的重大事项发表了客观、公正的意见，切实维护了公司和全体股东的合法权益。 现将2024年度工作情况报告如下: 一、独立董事基本情况 （一）工作履历、专业背景以及兼职情况 徐岱，女，出生于 1967 年 10 月，中共党员，法学博士，吉林大学法学院教 授、博士生导师，美国杜克大学访问学者，香港大学法律学院访问学者。全国法 律专业学位研究生教育指导委员会委员；中国刑法学研究会常务理事；中国犯罪 学学会副会长；国际刑法学协会暨中国分会理事；吉林省法学会刑法学研究会副 会长；吉林省法学会犯罪预防研究会常务副会长兼秘书长；吉林省 ...

通化东宝药业股份有限公司 章 程 二〇二五年四月 | 第一章 | 总则 ………………………………………………………………………………02 | | --- | --- | | 第二章 | 经营宗旨和范围 …………………………………………………………………03 | | 第三章 | 股份 ………………………………………………………………………………03 | | 第一节 | 股份发行 …………………………………………………………………………03 | | 第二节 | 股份增减和回购 …………………………………………………………………04 | | 第三节 | 股份转让 …………………………………………………………………………05 | | 第四章 | 股东和股东会 ……………………………………………………………………06 | | 第一节 | 股东 ………………………………………………………………………………06 | | 第二节 | 股东会的一般规定…………………………………………………………………09 | | 第三节 | 股东会的召集 ……………………………………………………………………12 | | 第四节 | 股东会的提 ...

通化东宝药业股份有限公司 2024年度独立董事述职报告（徐力） 作为通化东宝药业股份有限公司(以下简称"公司"或"本公司")的独立 董事,在2024年度内，本人严格按照《公司法》、《证券法》、《上市公司独立 董事管理办法》、《上海证券交易所上市公司自律监管指引第1号——规范运作》 等有关法律、法规的规定及《公司章程》的有关规定和要求，勤勉、忠实、尽责 地履行独立董事职责,不受公司控股股东、实际控制人或者其他与公司存在利害 关系的单位与个人的影响,积极出席公司股东大会和董事会,发挥专业特长,对公 司的重大事项发表了客观、公正的意见，切实维护了公司和全体股东的合法权益。 （二）独立董事独立性的情况说明 报告期内，本人任职符合《上市公司独立董事管理办法》等法律法规关于独 立性的要求，不存在影响独立性的情况。 二、独立董事 2024 年度履职概况 （一）出席会议情况 2024 年度公司共计召开了 1 次年度股东大会，4 次临时股东大会，11 次董 事会。本人均以现场或通讯方式参加了各次会议，没有缺席会议的情况。在会议 1 召开前，本人获取并详细审阅了公司提前准备的会议资料，会议上认真审议每一 个议题，积极参与讨论、提 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 651,502,983.92, representing a 10.17% increase compared to CNY 591,386,056.41 in the same period last year[4] - Net profit attributable to shareholders decreased by 49.15% to CNY 109,164,049.37 from CNY 214,676,914.76 year-on-year[4] - The basic and diluted earnings per share were both CNY 0.06, down 45.45% from CNY 0.11 in the previous year[4] - Net profit for Q1 2025 was ¥106.70 million, a decrease of 50.25% compared to ¥214.66 million in Q1 2024[21] - Total operating revenue for Q1 2025 reached ¥651.50 million, a 10.14% increase from ¥591.39 million in Q1 2024[20] Cash Flow - The net cash flow from operating activities was CNY 98,975,496.92, a decline of 35.43% compared to CNY 153,275,829.45 in the same period last year[4] - Operating cash flow for Q1 2025 was ¥98.98 million, down 35.38% from ¥153.28 million in Q1 2024[24] - The net cash flow from investing activities was -$117.22 million, compared to -$139.44 million in the previous period, indicating an improvement of approximately 15.9%[25] - The net cash flow from financing activities was $119.73 million, a significant increase from -$45.04 million in the prior period, reflecting a turnaround in financing operations[25] - The overall net increase in cash and cash equivalents was $101.49 million, contrasting with a decrease of $30.93 million in the previous period[25] Assets and Liabilities - Total assets increased by 2.30% to CNY 7,548,393,331.08 from CNY 7,378,510,669.69 at the end of the previous year[5] - Current assets reached CNY 2,097,221,781.28, compared to CNY 2,006,316,039.41 at the end of 2024, indicating an increase of about 4.67%[15] - The company's total liability was ¥1,036.61 million, an increase from ¥978.08 million in the previous period[18] - Total current liabilities rose to CNY 725,291,575.09 from CNY 665,442,834.24, reflecting an increase of about 9.00%[16] Expenses - Total operating costs increased to ¥565.67 million in Q1 2025, up 50.38% from ¥376.19 million in Q1 2024[20] - Research and development expenses rose to ¥37.63 million in Q1 2025, an increase of 39.36% from ¥27.02 million in Q1 2024[20] - Sales expenses for Q1 2025 were ¥251.64 million, up 37.59% from ¥182.84 million in Q1 2024[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 93,072[9] - The company reported a total of 599,749,787 shares held by Dongbao Industrial Group, accounting for 30.62% of total shares[12] - The top ten shareholders collectively hold a significant portion of the company's shares, with no shareholder participating in margin trading or securities lending[12] Other Financial Metrics - The weighted average return on equity decreased by 1.23 percentage points to 1.70% from 2.93% at the end of the previous year[5] - Non-recurring gains and losses amounted to a net loss of CNY 809,961.36, influenced by various factors including government subsidies and other operational losses[7] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[26]

Financial Performance - The net profit attributable to the parent company for 2024 is -42,723,162.30 CNY, with undistributed profits at 3,432,915,917.08 CNY[6]. - The company's operating revenue for 2024 was CNY 2,009,514,604.92, a decrease of 34.66% compared to CNY 3,075,416,029.21 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY -42,723,162.30, representing a decline of 103.66% from CNY 1,167,835,317.79 in 2023[22]. - The cash flow from operating activities for 2024 was CNY 459,740,577.53, down 46.64% from CNY 861,521,518.57 in 2023[22]. - Basic earnings per share for 2024 were CNY -0.02, a decrease of 103.39% compared to CNY 0.59 in 2023[23]. - The weighted average return on equity for 2024 was -0.63%, a decrease of 17.72 percentage points from 17.09% in 2023[25]. - The total profit for the company was -143.75 million RMB, representing a decline of 110.52% year-on-year[36]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -9.20 million RMB, a decrease of 100.79% year-on-year[36]. Dividend and Share Repurchase - The proposed cash dividend is 2.50 CNY per 10 shares, totaling 485,866,253.00 CNY (including tax), which represents 1,137.24% of the net profit[7]. - The total amount for cash dividends and share repurchases is 785,906,830.94 CNY, accounting for 1,839.53% of the net profit[7]. - The company has repurchased 15,077,817 shares, with a total repurchase amount of 300,040,577.94 CNY during the year[7]. - The company plans to maintain the per-share distribution ratio unchanged, with adjustments to the total distribution amount if the total share capital changes before the dividend record date[7]. - The company does not plan to issue new shares or convert reserves into share capital this year[7]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[9]. - The company’s future plans and development strategies are subject to investment risks and do not constitute a commitment to investors[8]. - The net profit decline was primarily attributed to decreased operating revenue and losses from terminated R&D projects[26]. - The company recognized a loss of CNY 253,523,550.00 related to a prepayment for commercialization rights, impacting the second quarter's net profit[28]. Market and Product Development - The company is focusing on expanding its overseas market and enhancing innovative drug research and development as part of its long-term strategy[35]. - The company achieved a significant breakthrough in hospital access, with approximately 1,400 new hospitals for glargine insulin and 5,000 new hospitals for premixed aspart insulin[40]. - The company is enhancing its diabetes management platform and POCT projects, aiming for comprehensive blood glucose management from admission to discharge[42]. - The company is actively promoting its products through various academic activities to improve brand awareness and market penetration[42]. - The company is focusing on developing products in the endocrine and metabolic treatment fields, including insulin analogs and oral hypoglycemic agents[105]. Research and Development - The company is expanding its research and development in the endocrine metabolism field, with ongoing projects including three new diabetes treatments and two new gout/hyperuricemia treatments[43]. - The company received clinical trial approval for its dual-target GLP-1/GIP agonist, with successful completion of phase Ia trials and ongoing phase Ib trials for both glycemic control and weight loss indications[45]. - The company is developing multiple new drugs targeting diabetes and gout, with several in various clinical trial phases[126]. - The company reported a research and development investment of 450.46 million RMB, representing a 7.15% increase compared to the previous year[132]. - The R&D investment accounted for 22.42% of the company's operating revenue and 7.04% of net assets during the reporting period[131]. Corporate Governance - The company held 1 annual general meeting and 4 temporary general meetings during the reporting period, ensuring compliance with legal requirements[166]. - The board of directors consists of 9 members, including 3 independent directors, and held 11 meetings during the reporting period[167]. - The company completed 4 periodic reports and 111 temporary announcements, ensuring timely and accurate information disclosure to investors[168]. - The company is enhancing its internal control systems to improve risk management and operational standards[168]. - The company confirmed that there are no significant accounting errors or fraud related to financial reports, maintaining compliance with relevant laws and regulations[193]. Strategic Partnerships and Market Position - The company has established a strategic partnership with Jianyou Co. to enter the U.S. insulin market, with production facilities meeting EU GMP standards[54]. - The company maintains a leading position in the diabetes treatment market, with over 40% market share in human insulin, solidifying its industry leadership[70]. - The company is recognized as a high-tech enterprise and has received multiple certifications, including GMP, enhancing its credibility in the pharmaceutical industry[71]. - The company is advancing its internationalization strategy, focusing on the registration of insulin and GLP-1RA products in overseas markets, while seeking partnerships with large foreign pharmaceutical companies[159]. Employee and Management Changes - The total number of employees in the parent company is 3,349, with 1,396 in sales, 1,050 in production, and 690 in technical roles[199]. - The company has a structured compensation committee that ensures compliance with relevant laws and regulations regarding remuneration[185]. - The company’s management has been actively involved in various other enterprises, indicating a broad network and potential for strategic partnerships[182]. - The company’s management team includes experienced professionals with backgrounds in various fields, enhancing its operational capabilities[176]. - Du Zhiqiang resigned as Vice General Manager due to personal reasons, effective March 31, 2025[180].

通化东宝药业股份有限公司 600867 2024 年度可持续发展报告 1 报告说明 关于本报告 此报告为通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"） 对外公布的《2024 年度可持续发展报告》。 时间范围 2024 年 1 月 1 日至 2024 年 12 月 31 日，为增强报告的可比性和完整性，部 分内容超出上述范围 报告范围 本报告以通化东宝药业股份有限公司为主体，涵盖通化东宝及其子公司。 除特别说明外，本报告范围与本公司年报范围保持一致。 编制依据 本报告遵循《上海证券交易所上市公司自律监管指引第 14 号—可持续发展 报告（试行）》，并结合本公司重大性议题分析结果进行编制而成。 指代说明 为便于表述和阅读，报告中的通化东宝药业股份有限公司根据行文具体情 况，简称为"通化东宝"、"东宝"、"公司"和"我们"。 数据说明 本报告引用的全部信息数据均来自于公司正式文件、统计报告与财务报告。 本报告素材由通化东宝及合作伙伴提供，目的仅供通化东宝可持续发展管理进展 披露使用，不用于商业用途。本报告的财务数据以人民币为单位。若与财务报告 不一致之处，以财务报告为准。 报告获取 本 报 告 电 子 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-029 通化东宝药业股份有限公司 2024年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》以及《上海证券交易所上市公司自律监管指南第 1 号——公告 格式》的相关规定，通化东宝药业股份有限公司（以下简称"本公司"或"公司"） 就 2024 年度募集资金存放与实际使用情况作如下专项报告： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2016]918 号文批准，本公司由主承销 商华泰联合证券有限责任公司采用非公开发行方式，向特定投资者非公开发行人 民币普通股（A 股）股票 55,726,976 股，发行价格为每股人民币 18.68 元，本次 发行共计募集资金人民币 1,040,979,911.68 元，扣除承销费用 19,948,774.13 元后 的募集资金 ...